Join to View Full Profile
1 Medical Center DrDepartment of HematologyoncologyLebanon, NH 03756
Phone+1 603-650-9474
Are you Dr. Pipas?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. J. Pipas, MD is an oncologist in Lebanon, New Hampshire. He is currently licensed to practice medicine in New Hampshire.
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1992 - 1994
Medical University of South CarolinaResidency, Internal Medicine, 1989 - 1992
SUNY Upstate Medical UniversityClass of 1989
Certifications & Licensure
NH State Medical License 1994 - 2022
Publications & Presentations
PubMed
- 1 citationsCorrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemci...M Kundranda, A C Gracian, S F Zafar, E Meiri, J Bendell
Annals of Oncology. 2020-08-01 - 40 citationsRandomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-...M. Kundranda, A.C. Gracian, S.F. Zafar, E. Meiri, Johanna C. Bendell
Annals of Oncology. 2020-01-01 - 33 citationsRandomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung CancerLecia V. Sequist, Jhanelle E. Gray, Wael A. Harb, Ariel Lopez-Chavez, Robert C. Doebele
The Oncologist. 2019-08-01
Press Mentions
GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee ReviewJuly 31st, 2024- Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee ReviewJuly 31st, 2024
